Download PDF
Thromb Haemost 2017; 117(03): 543-555
DOI: 10.1160/TH16-04-0317
Cellular Haemostasis and Platelets
Schattauer GmbH

Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

Harmanpreet Kaur
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada
,
Kathryn Corscadden
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada
,
Jerry Ware
2   Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
,
Maha Othman
1   Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada
3   School of Baccalaureate Nursing, St Lawrence College, Kingston, Ontario, Canada
› Author Affiliations Financial support: This research was supported by funding from the Canadian Hemophilia Society.
Further Information

Publication History

Received: 20 April 2016

Accepted after major revision: 26 November 2016

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Platelet defects due to hyper-responsive GPIbα causing enhanced VWF interaction, counter-intuitively result in bleeding rather than thrombosis. The historical explanation of platelet/VWF clearance fails to explain mechanisms of impaired haemostasis particularly in light of reported poor platelet binding to fibrinogen. This study aimed to evaluate the defects of platelets with hyper-responsive GPIbα and their contribution to impaired in vivo thrombosis. Using the PT-VWD mouse model, platelets from the hTgG233V were compared to control hTgWT mice. Platelets’ pro-coagulant capacity was evaluated using flowcytometry assessment of P-selectin and annexin V. Whole blood platelet aggregation in response to ADP, collagen and thrombin was tested. Clot kinetics using laser injury thrombosis model and the effect of GPIbα inhibition in vivo using 6B4; a monoclonal antibody, were evaluated. Thrombin-induced platelet P-selectin and PS exposure were significantly reduced in hTgG233V compared to hTgWT and not signifi-cantly different when compared to unstimulated platelets. The hTgG233V platelets aggregated normally in response to collagen, and had a delayed response to ADP and thrombin, when compared to hTgWT platelets. Laser injury showed significant impairment of in vivo thrombus formation in hTgG233V compared to hTgWT mice. There was a significant lag in in vitro clot formation in turbidity assay but no impairment in thrombin generation was observed using thromboelastography. The in vivo inhibition of GPIbα facilitated new – unstable – clot formation but did not improve the lag. We conclude platelets with hyper-responsive GPIbα have complex intrinsic defects beyond the previously described mechanisms. Abnormal signalling through GPIbα and potential therapy using inhibitors require further investigations.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

GPIbα inhibition - platelet activation - thrombin - platelet bleeding disorders - hyperresponsive GPIbα

 

  • References

  • 1 Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Intern J Biochem Cell Biol 1997; 29: 91-105.
    CrossrefPubMedGoogle Scholar
  • 2 Clemetson KJ, Clemetson JM. Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost 1995; 21: 130-136.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 2009; 35: 233-241.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Grainick HR, Williams SB, McKeown LP. et al. Von Willebrand’s disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76: 1522-1529.
    CrossrefPubMedGoogle Scholar
  • 5 De Marco L, Girolami A, Zimmerman TS. et al. Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci USA 1985; 82: 7424-7428.
    CrossrefPubMedGoogle Scholar
  • 6 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscl Thromb Vasc Biol 2002; 22: 1381-1389.
    CrossrefPubMedGoogle Scholar
  • 7 Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lopez JA, Andrews RK, Afshar-Kharghan V. et al. Bernard-Soulier syndrome. Blood 1998; 91: 4397-4418.
    PubMedGoogle Scholar
  • 9 Othman M, Kaur H, Favaloro EJ. et al. Platelet Type von Willebrand Disease and Registry Report: Communication from the SSC of the ISTH. J Thromb Haemost 2016; 14: 411-414.
    CrossrefPubMedGoogle Scholar
  • 10 Maurer M, Mesters R, Schneppenheim R. et al. Platelet-type von Willebrand Disease: Diagnostic Challenges. Flaws and Pitfalls Experienced in the THROMKID Quality Project. Klin Paediatr 2015; 227: 131-136.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Othman M. Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev 2011; 25: 147-153.
    CrossrefPubMedGoogle Scholar
  • 12 Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011; 37: 464-469.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Frontroth JP, Hepner M, Sciuccati G. et al. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost 2010; 104: 1158-1165.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-haemostasis coin?. Semin Thromb Hemost 2008; 34: 113-127.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Favaloro EJ, Patterson D, Denholm A. et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139: 623-626.
    CrossrefPubMedGoogle Scholar
  • 16 Suva LJ, Hartman E, Dilley JD. et al. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol 2008; 172: 430-439.
    CrossrefPubMedGoogle Scholar
  • 17 Guerrero JA, Kyei M, Russell S. et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood 2009; 114: 5541-5546.
    CrossrefPubMedGoogle Scholar
  • 18 Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-2808.
    CrossrefPubMedGoogle Scholar
  • 19 Cauwenberghs N, Meiring M, Vauterin S. et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscl Thromb Vasc Biol 2000; 20: 1347-1353.
    CrossrefPubMedGoogle Scholar
  • 20 Fontayne A, De Maeyer B, De Maeyer M. et al. Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. J Biol Chem 2007; 282: 23517-23524.
    CrossrefPubMedGoogle Scholar
  • 21 Wu D, Meiring M, Kotze HF. et al. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscl Thromb Vasc Biol 2002; 22: 323-328.
    CrossrefPubMedGoogle Scholar
  • 22 Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-2478.
    PubMedGoogle Scholar
  • 23 Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
    CrossrefPubMedGoogle Scholar
  • 24 Metassan S, Routledge MN, Lucking AJ. et al. Fibrin clot structure remains unaffected in young, healthy individuals after transient exposure to diesel exhaust. Particle Fibre Toxicol 2010; 07: 17.
    CrossrefPubMedGoogle Scholar
  • 25 Chou J, Mackman N, Merrill-Skoloff G. et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-3197.
    CrossrefPubMedGoogle Scholar
  • 26 Moos MP, Mewburn JD, Kan FW. et al. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J 2008; 22: 4352-4362.
    CrossrefPubMedGoogle Scholar
  • 27 Nishimura S, Manabe I, Nagasaki M. et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signalling. Blood 2012; 119: e45-56.
    CrossrefPubMedGoogle Scholar
  • 28 Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-547.
    CrossrefPubMedGoogle Scholar
  • 29 Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 2004; 18: 172-177.
    PubMedGoogle Scholar
  • 30 Ravanat C, Strassel C, Hechler B. et al. A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kDa GPIbalpha N-terminal extracellular domain. Blood 2010; 116: 1157-1164.
    CrossrefPubMedGoogle Scholar
  • 31 Giannini S, Cecchetti L, Mezzasoma AM. et al. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010; 95: 1021-1024.
    CrossrefPubMedGoogle Scholar
  • 32 Sánchez-Luceros A, Woods AI, Bermejo E. et al. PT-VWD posing diagnostic and therapeutic challenges- small case series. Platelets 2016; 07: 1-7.
    PubMedGoogle Scholar
  • 33 Fontayne A, Vanhoorelbeke K, Pareyn I. et al. Rational humanisation of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost 2006; 96: 671-684.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Andersen H, Greenberg DL, Fujikawa K. et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-11193.
    CrossrefPubMedGoogle Scholar
  • 35 Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42: 423-438.
    CrossrefPubMedGoogle Scholar
  • 36 Casari C, Berrou E, Lebret M. et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin alphaIIbbeta3. J Clin Invest 2013; 123: 5071-5081.
    CrossrefPubMedGoogle Scholar
  • 37 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-142.
    CrossrefPubMedGoogle Scholar
  • 38 Dunn EJ, Philippou H, Ariens RA. et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
    CrossrefPubMedGoogle Scholar
  • 39 Carr Jr. ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. The J Lab Clin Med 1996; 128: 83-88.
    PubMedGoogle Scholar
  • 40 Estevez B, Kim K, Delaney MK. et al. Signalling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood 2016; 127: 626-636.
    CrossrefPubMedGoogle Scholar
  • 41 Alberio L, Dale GL. Flow cytometric analysis of platelet activation by different collagen types present in the vessel wall. Br J Haematol 1998; 102: 1212-1218.
    CrossrefPubMedGoogle Scholar
  • 42 Bury L, Falcinelli E, Mezzasoma AM. et al. Defective alphaIIbbeta3 activation causes platelet dysfunction in von Willebrand disease platelet-type (PT-VWD). J Thromb Haemost 2015; 13 (Suppl. 02) 223.
    CrossrefPubMedGoogle Scholar